We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Crowdfunding Opportunities in Medical

AgPlus has created a diagnostic platform for detecting human diseases and delivering laboratory instrument results instantly, whilst keeping in mind the business requirements and unmet requirements. The company works in collaboration with leading diagnostics companies to improve and share products quickly and globally. It aims is to become known as a leader in Point of Care diagnosis.
investment: £905,005 target: £1,600,000
status: Active 6 days
to go


More Information
57% of Funding Target Achieved
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.
investment: £55,000 target: £400,000
status: Active 52 days
to go


More Information
14% of Funding Target Achieved
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
investment: Unknown target: £2,000,000
status: Active 112 days
to go


More Information
Stericile Ltd is a chemical R&D company that has scientifically created a disinfectant meant to combat the epidemic of Hospital Acquired Infections. The company has achieved the biggest technological advancement in the peracetic acid market, having spent over £400,000 to create a unique chemical solution for the healthcare market. Stericile Ltd has secured a UK national supplier that caters to 15,000+ healthcare customers such as dentist & doctor surgeries, care homes, and medical centres with less effective products.
investment: £160,270 target: £150,000 pre-money valuation: £1,750,000
status: Active 8 days
to go


More Information
107% of Funding Target Achieved
Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
investment: £600,000 target: £1,500,000
status: Active 112 days
to go


More Information
40% of Funding Target Achieved
International Ambulances (IA) aims to save lives and to provide better outcomes for patients, paramedics and hospitals. The company is building a revolutionary ambulance the 'ACESO' that will be the first ever purpose built global ambulance. ACESO will address known challenges of accident & emergency departments and promote the NHS 'See and Treat' strategy. Of the ambulance fleet size of 14,000, International Ambulances (IA) has identified about 1,200 A&E Ambulances of which the opportunity for ACESO is 500 per year. 
investment: £251,600 target: £1,000,025
25% of Funding Target Achieved
Olberon is a UK based medical device innovations company seeking to raise funds for manufacturing and the sale of Vacuderm which is a device designed to assist with childrens cannulation procedure. Olberon Ltd has already got a strong portfolio of patented medical innovations and two medical devices which are market ready.
investment: £5,634 target: £100,000 pre-money valuation: £1,399,250
6% of Funding Target Achieved
Arcis Biotechnology provide nucleic acid sample preparation solutions. They have made the process of obtaining genetic material from biological samples less time consuming so it can be done in less than 3 minutes.
investment: £1,146,318 target: £999,999 pre-money valuation: £19,202,001
115% of Funding Target Achieved
During their stay in hospital, around 7-10% of patients attract unexpected infections. In some cases, this is caused by unclean complex surgical tools. Aspetium have developed ultrasonic washers (dubbed "uSonic") to thoroughly decontaminate expensive surgical instruments, which can be safely reused to potentially prevent easily avoidable infections.
investment: £150,903 target: £90,009 pre-money valuation: £2,343,452
168% of Funding Target Achieved
Reducing the cost of orthopaedic equipment by using compression screws and titanium maxiangle locking plates. DC Surgical Supplies have acquired an exclusive license with Palmer & Baker with the aim of helping the NHS cut the cost of purchasing regular-use equipment by as much as 35%. Their product is CE Certified and has been featured in The Telegraph.
investment: £99,000 target: £325,000 pre-money valuation: £487,500
30% of Funding Target Achieved
Rightangled is a DNA testing company backed by NHS that delivers services to consumers and medical/fitness specialists. The company is a full CQC healthcare provider license that has achieved registration with Bupa, a leading medical insurance company. The company is now planning to move into AI with a solid database. Rightangled has received excellent customer reviews with 5* on Google and 4.5* on Trustpilot. With the proceeds, the company will seek to launch its application, create a strong AI central system, and grow into new markets (US& UAE).
investment: £518,180 target: £300,000 pre-money valuation: £5,998,135

ratings powered by CROWD RATING







Gold Rated
173% of Funding Target Achieved
Please watch the video for more information
investment: £360,250 target: £275,000 pre-money valuation: £4,076,266
131% of Funding Target Achieved
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph